MedPath

Furosemide

Generic Name
Furosemide
Brand Names
Furoscix, Lasix
Drug Type
Small Molecule
Chemical Formula
C12H11ClN2O5S
CAS Number
54-31-9
Unique Ingredient Identifier
7LXU5N7ZO5
Background

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.

Indication

Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.

Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.

Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.

Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.

Associated Conditions
Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion
Associated Therapies
-

Aquaresis Utility for Hyponatremic Acute Heart Failure Study

Phase 4
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2014-07-08
Last Posted Date
2019-05-28
Lead Sponsor
University of Southern California
Target Recruit Count
33
Registration Number
NCT02183792
Locations
🇺🇸

Keck Medical Center of USC, Los Angeles, California, United States

🇺🇸

LAC+USC Medical Center, Los Angeles, California, United States

Diuretics for Postpartum High Blood Pressure in Preeclampsia

Phase 4
Completed
Conditions
Preeclampsia
Interventions
Drug: Placebo
Drug: FUROSEMIDE
First Posted Date
2014-06-13
Last Posted Date
2024-10-02
Lead Sponsor
Instituto Materno Infantil Prof. Fernando Figueira
Target Recruit Count
120
Registration Number
NCT02163655
Locations
🇧🇷

IMIP, Recife, Pernambuco, Brazil

Effectiveness of a Diuretic Algorithm in Clinical Stability in Heart Failure Patients

Not Applicable
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2014-02-21
Last Posted Date
2020-04-22
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
206
Registration Number
NCT02068937
Locations
🇧🇷

Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)

Not Applicable
Withdrawn
Conditions
Congestive Heart Failure
Interventions
Drug: furosemid/spironolactone
Drug: metolazone/spironolactone
Drug: metolazone
Drug: Furosemide
First Posted Date
2014-01-28
Last Posted Date
2016-09-07
Lead Sponsor
Yonsei University
Registration Number
NCT02047422

The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure

Phase 4
Conditions
Heart Failure
Interventions
First Posted Date
2013-09-13
Last Posted Date
2017-06-08
Lead Sponsor
Medical University of Warsaw
Target Recruit Count
100
Registration Number
NCT01942109
Locations
🇵🇱

3rd Clinic of Internal Medicine and Cardiology of Medcial University of Warsaw, Warsaw, Mazowieckie, Poland

🇵🇱

1st Department of Cariology of Medcial University of Warsaw, Warsaw, Mazowieckie, Poland

Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction

Phase 4
Completed
Conditions
Heart Failure, Diastolic
Interventions
First Posted Date
2013-07-17
Last Posted Date
2018-08-16
Lead Sponsor
Johns Hopkins University
Target Recruit Count
90
Registration Number
NCT01901809
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

Inhaled Nebulized Furosemide & Physical Activity-Related Breathlessness

Phase 1
Conditions
Breathlessness
Interventions
Other: CWS
Drug: Placebo
Drug: Furosemide
First Posted Date
2013-05-13
Last Posted Date
2017-02-14
Lead Sponsor
McGill University
Target Recruit Count
30
Registration Number
NCT01851980
Locations
🇨🇦

Centre of Innovative Medicine of the McGill University Health Centre, Montreal, Quebec, Canada

Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis

Phase 1
Completed
Conditions
Renal Failure
Interventions
First Posted Date
2012-11-12
Last Posted Date
2013-02-12
Lead Sponsor
Sanofi
Target Recruit Count
12
Registration Number
NCT01724788
Locations
🇨🇦

Investigational Site Number 124002, Montreal, Canada

Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass

Not Applicable
Completed
Conditions
Acute Kidney Injury
Interventions
Procedure: Peritoneal Dialysis
Drug: Furosemide
First Posted Date
2012-10-18
Last Posted Date
2017-06-09
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
73
Registration Number
NCT01709227
Locations
🇺🇸

Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States

Furosemide Treatment Before Blood Transfusion in Patients With Systolic Dysfunction

Not Applicable
Withdrawn
Conditions
Anemia Treatment Among Patients Suffering From Left Ventricular Systolic Dysfunction
Interventions
Drug: placebo normal saline
Drug: furosemide
First Posted Date
2012-10-12
Last Posted Date
2016-06-28
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Registration Number
NCT01705470
© Copyright 2025. All Rights Reserved by MedPath